XNAS · Healthcare · Biotechnology
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -1.28 | -0.41 | +67.97% | $5.0M | ✅ Beat | +1.76% | +9.66% | — |
| 2026-05-06 | Q1 2026 | -0.85 | -11.65 | -1270.59% | $5.0M | ❌ Miss | +0.00% | -11.69% | -36.95% |
| 2026-03-23 |
| Q4 2025 |
| -1.30 |
| -20.13 |
| -1448.46% |
| $500,000 |
| ❌ Miss |
| -0.28% |
| +8.76% |
| +30.86% |
| 2025-11-07 | Q3 2025 | -1.17 | -8.36 | -614.53% | $983,000 | ❌ Miss | — | — | — |
| 2025-08-08 | Q2 2025 | -1.23 | 2.55 | +307.32% | $983,000 | ✅ Beat | -0.63% | +16.53% | +18.83% |
| 2025-03-31 | Q4 2024 | -2.64 | -9.10 | -244.70% | $0 | ❌ Miss | -4.63% | -15.95% | -5.57% |
| 2024-08-12 | Q2 2024 | -2.79 | -7.99 | -186.38% | $0 | ❌ Miss | -10.14% | +6.85% | +14.93% |
| 2024-05-08 | Q1 2024 | -4.25 | -4.24 | +0.24% | $0 | ✅ Beat | +0.29% | -0.47% | +8.73% |
Showing last 8 quarters.